Palatin Technologies Inc (PTNTD)

Currency in USD
10.6600
+1.2500(+13.28%)
Closed·
PTNTD Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
PTNTD is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
10.250010.7500
52 wk Range
1.750086.0000
Key Statistics
Prev. Close
9.41
Open
10.49
Day's Range
10.25-10.75
52 wk Range
1.75-86
Volume
5.95K
Average Volume (3m)
8.92K
1-Year Change
-87.78%
Book Value / Share
-12.28
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PTNTD Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Palatin Technologies Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Palatin Technologies Inc Company Profile

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company’s lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. Palatin Technologies, Inc. was founded in 1986 and is based in Cranbury, New Jersey.

Palatin Technologies Inc Earnings Call Summary for Q3/2025

  • Q3 FY2025 net loss narrowed to $4.8M from $8.4M YoY; EPS of -$0.18 beat -$0.46 forecast
  • No product sales due to Vyleesi rights sale; cash and equivalents at $2.5M, with $3.5M received post-quarter
  • FDA granted orphan drug status to PL7737; NDA submission planned for Q1 2026, pending financing
  • Delisted from NYSE American, now on OTC Pink; seeking new funding and business development opportunities
  • Executives highlight early stage of obesity treatment innovation; partnerships for ulcerative colitis and dry eye programs expected H2 2025
Last Updated: 14/05/2025, 16:38
Read Full Transcript

Compare PTNTD to Peers and Sector

Metrics to compare
PTNTD
Peers
Sector
Relationship
P/E Ratio
−0.3x−3.0x−0.6x
PEG Ratio
−0.010.010.00
Price/Book
−1.0x2.3x2.6x
Price / LTM Sales
19.1x8.2x3.3x
Upside (Analyst Target)
-123.3%37.4%
Fair Value Upside
Unlock12.5%4.5%Unlock

Earnings

Latest Release
May 14, 2025
EPS / Forecast
-9.13 / -0.46
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

PTNTD Income Statement

People Also Watch

18.06
SRPT
-10.68%
0.121
WINT
-7.15%
2.26
INMB
-6.22%
49.55
BMNR
-7.38%
8.2840
SAN
-0.38%

FAQ

What Stock Exchange Does Palatin Trade On?

Palatin is listed and trades on the OTC Markets stock exchange.

What Is the Stock Symbol for Palatin?

The stock symbol for Palatin is "PTNTD."

What Is the Palatin Market Cap?

As of today, Palatin market cap is 10.18M.

What Is Palatin's Earnings Per Share (TTM)?

The Palatin EPS (TTM) is -55.89.

When Is the Next Palatin Earnings Date?

Palatin will release its next earnings report on 06 Oct 2025.

From a Technical Analysis Perspective, Is PTNTD a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Palatin Stock Split?

Palatin has split 5 times.

How Many Employees Does Palatin Have?

Palatin has 30 employees.

What is the current trading status of Palatin (PTNTD)?

As of 25 Aug 2025, Palatin (PTNTD) is trading at a price of 10.66, with a previous close of 9.41. The stock has fluctuated within a day range of 10.25 to 10.75, while its 52-week range spans from 1.75 to 86.00.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.